Predict your next investment

iCubate company logo
HEALTHCARE | Medical Devices & Equipment / Imaging & Diagnostic Equipment
icubate.com

See what CB Insights has to offer

Founded Year

2009

About iCubate

iCubate is a molecular diagnostic company with a multiplex polymerase chain reaction (mPCR) technology; a platform for automated sample preparation, amplification and detection called the iCubate System, or iC-System; and a product line for infectious disease diagnostics and research applications which involves syndromic testing for the identification and detection of organisms associated with bloodstream infections and subsequent sepsis.

iCubate Headquarter Location

601 Genome Way

Huntsville, Alabama, 35806,

United States

855-256-3330

Latest iCubate News

iCubate lung infection test secures FDA breakthrough status

Aug 7, 2019

Dive Brief: FDA has awarded breakthrough device status to iCubate’s assay for detecting and identifying potentially pathogenic non-tuberculosis Mycobacterium (NTM), the company announced last week. The Huntsville, Alabama in vitro diagnostics-maker designed the test to identify the six NTM species that most commonly cause pulmonary infections directly from decontaminated sputum samples. By eliminating the need to culture samples, iCubate said it can accelerate the diagnosis and treatment of a disease that affects more than 80,000 people in the U.S. Dive Insight: Lung infections with NTM can cause progressive disease characterized by symptoms such as cough, fatigue and weight loss. The American Lung Association said early diagnosis is essential for good outcomes, but the culture of a respiratory specimen is also required to make a definitive diagnosis. British Thoracic Society guidelines published in 2017 flesh out what that means in practice. The guidelines state samples should be cultured "for 8 weeks extending to 12 if necessary" and advise against the routine use of faster, non-culture-based detection methods. iCubate wants to change how NTM infections are diagnosed. To accelerate the process, iCubate is developing a multiplexed in vitro diagnostic, called iC-Myco Assay, that identifies the six bacterial species that typically cause NTM lung infections. The tests come on a cassette preloaded with the reagents required to amplify and detect bacteria in the sample. Other pieces of iCubate equipment are needed to process and analyze the samples. Once a sample is added to a cassette, the assay is loaded into iCubate’s Processor. This device performs automated sample preparation, after which the cassette is loaded into iCubate’s Reader for analysis. The lack of a culture step in the process means iCubate’s process is faster than existing standard methods for detecting NTM pathogens. However, there is evidence that the speed of the test is only one of the barriers to fast diagnoses. When FDA met with NTM lung infection patients in 2015, the agency found everyone "reported having symptoms for several years prior to a formal diagnosis." Securing the FDA breakthrough designation boosts iCubate’s chances of cutting the time it takes to diagnose NTM infections. Prior to potential approval, iCubate will benefit from more frequent interactions with FDA and potentially expedited review. Once on the market, iCubate may benefit from a CMS rule that changes the reimbursement process for breakthrough inpatient , and possibly outpatient , devices. As of Aug. 1, FDA had given breakthrough status to 186 devices over the course of the program's more than four-year history. iCubate currently markets an assay for detection and identification of potentially pathogenic gram positive bacteria, which can cause bloodstream infection, which won 510(k) clearance in 2017 . Recommended Reading:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing iCubate

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iCubate is included in 2 Expert Collections, including Medical Devices.

M

Medical Devices

10,912 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

701 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

iCubate Patents

iCubate has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Graphical control elements
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/5/2018

1/26/2021

Molecular biology, Graphical control elements, Biotechnology, Polymerase chain reaction, Molecular biology techniques

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

12/5/2018

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/26/2021

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Molecular biology, Graphical control elements, Biotechnology, Polymerase chain reaction, Molecular biology techniques

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.